Background. Colorectal cancer in young patients (40 years of age or younger) often is considered to have a worse prognosis than in older patients. The authors studied tumor DNA status and stage of disease to determine whether tumors in younger patients behaved differently from tumors in older patien
S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients
โ Scribed by Stefano Cascinu; Elena Del Ferro; Cesare Grianti; Marco Ligi; Giuseppina Catalano
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 333 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
Young patients with colorectal carcinomas are considered to have a worse prognosis than older patients. It was the goal of this study to assess if biologic characteristics of tumors in young patients differ from those observed in 2 different groups of patients with the same clinical characteristics but ranging in age either from 41 to 60 years or 61 years and older, respectively.
METHODS.
Colorectal carcinoma tumor samples were obtained from storage from patients age 40 years and younger and examined for tumor ploidy and S-phase fraction. For each younger patient, a control was selected among patients matched for Dukes stage, site of primary tumor, and sex, with the two age groups. RESULTS. Thirty-one of 1361 patients (2.2%) with colorectal carcinoma treated at our institution between 1984 and 1994 age 40 years or younger. Tumor aneuploidy was present in 3 younger patients, in 5 patients in the 41 to 60 years age group, and in 5 patients in the 61 years and older age group. S-phase fraction was 27.67 t-13.62 in patients younger than 40 years, 25.35 2 11.6 in the 40 to 61 years age group, and 22.45 i 8.48 in the 61 years and older age group. These differences were not statistically significant. CONCLUSIONS. It appears that there are no significant differences in S-phase fraction and tumor aneuploidy in patients younger or older than 40 years, suggesting that colorectal tumors arising in young people do not have different biologic properties.
๐ SIMILAR VOLUMES
BACKGROUND. Adjuvant chemotherapy for colorectal carcinoma was found to improve survival of patients with American Joint Committee on Cancer/International Union Against Cancer Stage III disease. The usefulness of chemotherapy in patients with Stage II disease continues to be debated, and it is likel
T he report by Shim et al. 1 in this issue of Cancer presents interesting data regarding the potential use of serum transforming growth factor (TGF)-โค1 levels as a tumor marker in patients with colorectal carcinoma. Their findings suggest that TGF-โค may be helpful in predicting extent of disease and
Background and Objectives: Parameters that allow prediction of the disease course in colorectal cancer would aid the development of improved treatment strategies. For this reason, we evaluated the prognostic value of flow cytometric DNA ploidy and S-phase fraction (SPF) and P-glycoprotein (Pgp) expr
## Background: Mutations of the p53 tumor suppressor gene play an integral role in sporadic colorectal carcinogenesis but prior studies have failed to show their prognostic significance consistently. ## Methods: Fifty-six consecutive sporadic colorectal tumors were analyzed for their p53 status.